About US
Contact us
-
Roche expects to keep Rituxan monopoly until 2015You know the patent-cliff drill: Companies can count down the days until their biggest drugs lose exclusivity--and they do. Not so for biologic treatments, even now that FDA has a pathway for biosim2012/9/7
-
JAMA says FDA jumped the gun on Gilenya, PradaxaThe FDA's balancing act is no easy feat. In fact, it just might be impossible. As soon as the agency gets congressional direction to revamp and speed up approvals, experts in other quarters conclu2012/9/6
-
Roche displays the fruits of $9B in R&D spendingIf Roche ($RHHBY) had a drug-development trading card, its stats would look something like this: R&D budget of $9 billion, with 72 development programs, 19 late-stage studies and 12 candidates f2012/9/6
-
Sanofi plans to buy back $152M in Genzyme CVRsSanofi ($SNY) plans to buy back up to $152 million in contingent value rights linked to last year's buyout of Genzyme. The French drugmaker says it would purchase about 30% of the CVRs, which pay of2012/9/5
-
J&J's Zytiga gets early challenge from Medivation's new pillAstellas Pharma and Medivation ($MDVN) won FDA approval for their prostate cancer treatment Xtandi three months ahead of schedule. That's welcome news for them--but perhaps not so welcome for compet2012/9/5
-
Pfizer, Boehringer drug delays asthma attacksA lung drug developed by Boehringer Ingelheim and Pfizer helped delay severe asthma attacks in adults during two last-stage trials, according to data presented at the 2012 European Respiratory Society2012/9/4
-
Roche drug may provide lifeline to tamoxifen-resistant breast cancer patientsScientists in the US have demonstrated how Roche's drug Erivedge (vismodegib) could act as a targeted therapy for breast cancer. A study conducted by researchers at the Ohio State University Comprehe2012/9/4
-
.Lilly pulls schizophrenia treatment after Phase III failureEli Lilly's experimental schizophrenia treatment pomaglumetad methionil has suffered a failure in a Phase III study, forcing the company to pull the drug from further development. The drug, also know2012/9/3
-
Roche drug may provide lifeline to tamoxifen-resistant breast cancer patientsScientists in the US have demonstrated how Roche's drug Erivedge (vismodegib) could act as a targeted therapy for breast cancer. A study conducted by researchers at the Ohio State University Comprehe2012/9/3
-
J&J to pay states $181M to resolve Risperdal casesIn what is probably a prelude to the much larger settlement that Johnson & Johnson ($JNJ) has indicated it has hammered out with federal authorities, the company said today that it has reached a s2012/8/31